

Grants Awarded through Expression of Interest Process

1 December 2021 to 30 September 2022

ANTIVIRAL STRATEGIES	
Prof Melissa Churchill	Ex vivo human organotypic brain slice cultures as a powerful tool to advance NeuroHIV cure strategies
Dr Felicity Han	Evaluation of Enfuvirtide-loaded nanoparticles for oral administration - new treatment option for HIV/AIDS
Dr Mina John	Drug and immune resistance in HIV intact proviral DNA under oral versus long-acting antiretroviral therapy
Dr Youry Kim	Combining pro-apoptotic drugs with latency reversing agents to kill HIV latently infected cells
Prof Sharon Lewin	Lipid nanoparticle-based delivery of HIV-reactivating RNAs to eradicate the latent reservoir
Dr Li Li	Dual pH and thermo-responsive microbicide hydrogels for HIV/AIDS prevention
Dr Margaret Littlejohn	Pre-clinical validation of CRISPR-Cas13 as a new therapeutic approach targeting hepatitis B virus RNA
Prof Gilda Tachedjian	Towards a multipurpose prevention technology for preventing HIV, STIs and unplanned pregnancies
DIAGNOSTICS/PROGNOSTICS	
Dr Rob Center	Development of improved point of care tests for diagnosis of viral hepatitis induced liver disease
Dr Belinda de Villiers	Refinement of HTLV-1 POC for remote settings
Dr Gavin Knott	CRISPR-detection for HBV prognostics
Dr Avik Majumdar	Evaluating circulating fibroblast activation protein as a point of care test for fibrosis assessment in Hepatitis B
Dr Nick Vandegraaff	Design, development and validation of improved HTLV proviral load (PVL) and antibody test systems
A/Prof Xionan Zhang	Performance of the pre-diagnostic pilot ELISA assay for capsid-antibody-complex in HBV mono-infection and HIV/HBV co-infection
VACCINES/PREVENTION AND IMMUNOTHERAPY	
A/Prof David Anderson	Immunotherapy to break HBsAg tolerance in chronic HBV infection
Prof Heidi Drummer	mRNA vaccines for HCV
Prof Tony Cunningham	Development of dual specific CAR T cell therapy after Interferon alpha pretreatment to eliminate the latent HIV-CD4 T cell reservoir